Kelly E. Anderson

1.2k total citations · 1 hit paper
46 papers, 776 citations indexed

About

Kelly E. Anderson is a scholar working on Economics and Econometrics, General Health Professions and Pediatrics, Perinatology and Child Health. According to data from OpenAlex, Kelly E. Anderson has authored 46 papers receiving a total of 776 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Economics and Econometrics, 9 papers in General Health Professions and 8 papers in Pediatrics, Perinatology and Child Health. Recurrent topics in Kelly E. Anderson's work include Pharmaceutical Economics and Policy (12 papers), Health Systems, Economic Evaluations, Quality of Life (10 papers) and Healthcare Policy and Management (7 papers). Kelly E. Anderson is often cited by papers focused on Pharmaceutical Economics and Policy (12 papers), Health Systems, Economic Evaluations, Quality of Life (10 papers) and Healthcare Policy and Management (7 papers). Kelly E. Anderson collaborates with scholars based in United States, Hungary and Italy. Kelly E. Anderson's co-authors include Rachel Presskreischer, Emma E. McGinty, Colleen L. Barry, Hahrie Han, R. Handgretinger, R. Dopfer, D. Niethammer, P. Reuland, S. D. Gillies and R. Reisfeld and has published in prestigious journals such as JAMA, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Kelly E. Anderson

38 papers receiving 753 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Reports of Forgone Medical Care Among US Adults During the Initial Phase of the COVID-19 Pandemic

2021 145 citations Kelly E. Anderson, Emma E. McGinty et al. JAMA Network Open profile →

Peers

Countries citing papers authored by Kelly E. Anderson

Since Specialization

Citations

This map shows the geographic impact of Kelly E. Anderson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kelly E. Anderson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kelly E. Anderson more than expected).

Fields of papers citing papers by Kelly E. Anderson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kelly E. Anderson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kelly E. Anderson. The network helps show where Kelly E. Anderson may publish in the future.

Co-authorship network of co-authors of Kelly E. Anderson

This figure shows the co-authorship network connecting the top 25 collaborators of Kelly E. Anderson. A scholar is included among the top collaborators of Kelly E. Anderson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kelly E. Anderson. Kelly E. Anderson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Using prescription medication utilization trends to evaluate health system resilience and inform future emergency preparedness 2025 ·Journal of Managed Care & Specialty Pharmacy ·(unknown), (unknown), (unknown), (unknown), Kelly E. Anderson	0
2	Innovative Payment Models for Sickle-Cell Disease Gene Therapies in Medicaid: Leveraging Real-World Data and Insights from CMMI’s Gene Therapy Access Model 2025 ·PharmacoEconomics ·Antal Zemplényi, Jim Leonard, (unknown), Michael J. DiStefano, Kavita V. Nair, Kelly E. Anderson, R. Brett McQueen	3
3	Impact of recently initiated medications on the incidence of urinary tract infections in patients with type 2 diabetes: an observational case-control study 2025 ·Therapeutic Advances in Drug Safety ·(unknown), Andrew M. Simons, (unknown), Kelly E. Anderson	0
4	Measuring Geographic Access to Pharmacies 2025 ·JAMA Network Open ·Kelly E. Anderson, T. Joseph Mattingly	0
5	Improving Affordability of Pharmaceutical Treatments for Diabetes: A Call for Action 2025 ·Diabetes Care ·Mariana P. Socal, Namratha R. Kandula, (unknown), Jeromie Ballreich, (unknown), Soyeon Kang, (unknown), Kelly E. Anderson, (unknown), Fernando Gerchman, Joseph Levy	0
6	Osteoporosis testing and treatment remain low in both Traditional Medicare and Medicare Advantage 2024 ·Osteoporosis International ·Tej D. Azad, Rachel J. Wu, Kelly E. Anderson, Michael Darden, Amit Jain	0
7	Medicare Advantage plan characteristics associated with sorting their beneficiaries to providers that generate fewer avoidable hospital stays 2024 ·Health Services Research ·(unknown), Kelly E. Anderson, Angela Liu, Daniel Polsky	1
8	Macular Degeneration Drug Prescribing Patterns After Step Therapy Introduction in Medicare Advantage 2024 ·JAMA Health Forum ·Angela Liu, Kelly E. Anderson, Joseph Levy, Thomas V. Johnson, Daniel Polsky, Gerard F. Anderson	1
9	State Out-Of-Pocket Caps On Insulin Costs: No Significant Increase In Claims Or Utilization 2024 ·Health Affairs ·Kelly E. Anderson, (unknown), (unknown), (unknown), Michael R. Rose, Diana Brixner, R. Brett McQueen	5
10	Role of Patient Sorting in Avoidable Hospital Stays in Medicare Advantage vs Traditional Medicare 2023 ·JAMA Health Forum ·(unknown), Kelly E. Anderson, Angela Liu, Brian J. Miller, Daniel Polsky	5
11	Incorporating Dynamic Pricing in Cost-Effectiveness Analysis: Are Known Unknowns Valuable? 2023 ·PharmacoEconomics ·R. Brett McQueen, Kelly E. Anderson, Joseph Levy, Josh J. Carlson	5
12	Filgrastim and infliximab biosimilar uptake in Medicare Advantage compared with Traditional Medicare, 2016-2019 2023 ·Journal of Managed Care & Specialty Pharmacy ·Angela Liu, (unknown), Mariana P. Socal, Gerard F. Anderson, Kelly E. Anderson	5
13	Is there an advantage? Considerations for researchers studying the effects of the type of Medicare coverage 2023 ·Health Services Research ·Lauren Hersch Nicholas, (unknown), Michael Darden, (unknown), Kelly E. Anderson, David J. Meyers	9
14	Alternative approaches to measuring value: an update on innovative methods in the context of the United States Medicare drug price negotiation program 2023 ·Expert Review of Pharmacoeconomics & Outcomes Research ·Michael J. DiStefano, Antal Zemplényi, Kelly E. Anderson, (unknown), Kavita V. Nair, R. Brett McQueen	1
15	Reports of Forgone Medical Care Among US Adults During the Initial Phase of the COVID-19 Pandemic breakdown → 2021 ·JAMA Network Open ·Kelly E. Anderson, Emma E. McGinty, Rachel Presskreischer, Colleen L. Barry	145
16	Cost-effectiveness Analysis of Screening Extremely Low Birth Weight Children for Hepatoblastoma Using Serum Alpha-fetoprotein 2020 ·The Journal of Pediatrics ·(unknown), Kelly E. Anderson, (unknown), Philippa G. Sprinz, William V. Padula	2
17	Biosimilar Uptake in Medicare Part B Varied Across Hospital Outpatient Departments and Physician Practices: The Case of Filgrastim 2020 ·Value in Health ·Mariana P. Socal, Kelly E. Anderson, Aditi P. Sen, Ge Bai, Gerard F. Anderson	20
18	COG AAML03P1: Efficacy and Safety in a Pilot Study of Intensive Chemotherapy Including Gemtuzumab in Children Newly Diagnosed with Acute Myeloid Leukemia (AML) 2008 ·Blood ·Janet Franklin, Todd A. Alonzo, Craig A. Hurwitz, Robert B. Gerbing, Franklin O. Smith, R.J. Arceci, James H. Feusner, Prasad Mathew, Robert Iannone, Soheil Meshinchi, Robert S. Lavey, (unknown), Kelly E. Anderson, Laura Winter, Kathleen Glick, (unknown), Susana C. Raimondi, Alan S. Gamis	16
19	Environmental chemical exposures and disturbances of heme synthesis. 1997 ·Environmental Health Perspectives ·William Daniell, (unknown), Robert F. Labbé, James S. Woods, Kelly E. Anderson, D. Montgomery Bissell, Joseph R. Bloomer, Ralph D. Ellefson, Michael Moore, Claus A. Pierach, William E. Schreiber, Ayalew Tefferi, Gary M. Franklin	62
20	Project SWINGs Kids into the Classroom. 1981 ·Children today ·Kelly E. Anderson	0

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact